BIOX Bioceres Crop Solutions Corp Forecast, Technical & Fundamental Analysis
Bioceres Crop Solutions Corp is a fully integrated provider of crop productivity solutions, including seeds, seed traits, seed treatments, biologicals, high-value adjuvants, and fertilizers... Show more
BIOX is expected to report earnings to fall 61.83% to -5 cents per share on September 03
Q2'26
Est.
$-0.06
Q1'26
Missed
by $0.11
Q4'25
Missed
by $0.15
Q3'25
Missed
by $0.15
Q2'25
Missed
by $0.78
The last earnings report on May 11 showed earnings per share of -15 cents, missing the estimate of -5 cents. With 783.11K shares outstanding, the current market capitalization sits at 23.80M.
A.I. Advisor
published General Information
General Information
a manager of investments in agricultural biotechnology
A.I.dvisor tells us that BIOX and FMC have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BIOX and FMC's prices will move in lockstep.
The Aroon Indicator for BIOX entered a downward trend on May 26, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 286 similar instances where the Aroon Indicator formed such a pattern. In of the 286 cases the stock moved lower. This puts the odds of a downward move at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on June 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BIOX as a result. In of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for BIOX turned negative on June 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .
BIOX moved below its 50-day moving average on June 03, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIOX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
BIOX broke above its upper Bollinger Band on June 01, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for BIOX's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BIOX advanced for three days, in of 235 cases, the price rose further within the following month. The odds of a continued upward trend are .
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. BIOX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.352) is normal, around the industry mean (1.324). BIOX's P/E Ratio (194.850) is considerably higher than the industry average of (46.501). Projected Growth (PEG Ratio) (1.236) is also within normal values, averaging (1.609). BIOX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.046). BIOX's P/S Ratio (0.081) is slightly lower than the industry average of (1.394).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIOX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
